-

The Global T-cell Therapy Market 2025-2030 by Therapy Type, Indication and Region - Shift Towards Allogeneic Platforms to Boost Market Accessibility - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's offering.

The Global T-cell Therapy Market, valued at USD 2.92 Billion in 2024, is projected to experience a CAGR of 9.90% to reach USD 5.14 Billion by 2030. The market's expansion is significantly propelled by the increasing global prevalence of various cancers, continuous technological advancements in genetic engineering techniques, and substantial investments directed towards research and development for novel immunotherapeutic approaches.

Key Market Drivers

The escalating global burden of cancer presents a substantial and persistent demand driver for innovative therapeutic solutions, including T-cell therapy. The increasing incidence of various cancer types globally necessitates the continuous development and adoption of advanced treatment modalities that offer improved efficacy and patient outcomes, particularly for those refractory to conventional therapies. This pressing medical need directly fuels investment and research into T-cell therapies, positioning them as critical options in oncology.

According to the American Cancer Society and the International Agency for Research on Cancer, April 2024, Global Cancer Statistics 2024, close to 20 million cancer cases were newly diagnosed in 2022 around the world, underscoring the vast and growing patient population requiring novel interventions.

Key Market Challenges

The inherently high cost associated with personalized T-cell therapies, driven by complex and resource-intensive manufacturing processes, presents a significant impediment to market expansion. These treatments necessitate individual modification of a patient's own T-cells, leading to high production expenses.

This directly restricts widespread patient access and imposes considerable financial pressure on healthcare systems and payers globally. Consequently, the adoption rate of these innovative therapies is constrained, preventing broader market penetration despite their demonstrated clinical efficacy.

Key Market Trends

The shift towards allogeneic T-cell therapies represents a significant evolutionary step in the global T-cell therapy market, moving away from individualized autologous treatments which rely on a patient's own cells. This transition aims to address the inherent manufacturing complexities and high costs associated with personalized therapies, paving the way for more readily available, "off-the-shelf" products. These allogeneic platforms, utilizing donor cells, hold the potential to enhance scalability and accessibility, thereby broadening the eligible patient population.

According to the Alliance for Regenerative Medicine, in January 2024, the sector anticipated the potential for the first United States approval of an allogeneic T-cell therapy that year.

Key Market Players Profiled:

  • Novartis AG
  • Merck KGaA
  • Gilead Sciences Inc.
  • TCR2 Therapeutics Inc.
  • Bluebird Bio Inc.
  • Sorrento Therapeutics Inc.
  • Fate Therapeutics Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Celgene Corporation

Report Scope

In this report, the Global T-cell Therapy Market has been segmented into the following categories:

By Therapy Type:

  • CAR T-cell Therapy
  • T Cell Receptor (TCR)-based
  • Tumor Infiltrating Lymphocytes (TIL)-based

By Indication:

  • Hematologic Malignancies
  • Solid Tumors
  • Others

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Key Attributes

Report Attribute Details
No. of Pages 183
Forecast Period 2024-2030
Estimated Market Value (USD) in 2024 $2.92 Billion
Forecasted Market Value (USD) by 2030 $5.14 Billion
Compound Annual Growth Rate 9.9%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/vy2003

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Expert-Led Training Course: Managing and Evaluating Bids & Tenders (Online: May 21st-22nd, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Managing and Evaluating Bids and Tenders Training Course (May 21st - May 22nd, 2026)" training has been added to ResearchAndMarkets.com's offering. This two-day course will provide participants with a powerful insight on how to successfully prepare and evaluate tenders and how to submit proposals in response to a tender. The course will also focus on the step-by-step process of bid and tender management, right from tender planning through to the award phase. The ex...

Effective Technical Writing & Editing: Expert-Led Online Training Course (May 15, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Effective Technical Writing & Editing Training Course (May 15, 2026)" has been added to ResearchAndMarkets.com's offering. Effective technical writing and editing is a vital skill in ensuring a clear and compliant message. This interactive course will provide an intensive, practical guide to best practice to follow in achieving excellence in scientific, medical and technical documentation. Our expert trainer will offer invaluable tools and techniques to help yo...

Best Practices for Supplier Qualification in Life Science: Online Training Course (May 6th-7th, 2026) with 12 CPD Hours - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Best Practices for Supplier Qualification in Life Science Training Course (May 6th - May 7th, 2026)" has been added to ResearchAndMarkets.com's offering. Conduct thorough supplier qualifications and audits to strengthen the quality systems of your pharmaceutical, biotechnology, and medical device manufacturing processes. Ensuring suppliers consistently meet quality requirements is paramount across all materials and services procured. Regulatory agencies such as FDA...
Back to Newsroom